Pediatrix Medical Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MD research report →
Range $25 – $28
Price Chart
About the company
Pediatrix Medical Group, Inc. delivers specialized medical services for newborns, expectant mothers, and pediatric patients across the United States and Puerto Rico. The company offers crucial neonatal care to critically ill or prematurely born infants within hospital units, staffed by expert neonatal subspecialists and advanced practice clinicians.
- CEO
- Mark S. Ordan
- IPO
- 1995
- Employees
- 4,280
- HQ
- Sunrise, FL, US
Get TickerSpark's AI analysis on MD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.36B
- P/E
- 16.16
- Fwd P/E
- 12.49
- PEG
- -15.27
- P/S
- 1.21
- P/B
- 2.75
- EV/EBITDA
- 10.64
- Div Yield
- 0.00%
- Gross Margin
- 25.83%
- Op Margin
- 11.40%
- Net Margin
- 7.66%
- ROE
- 17.28%
- ROIC
- 9.18%
Latest fiscal year · YoY change
- Revenue
- $1.91B-4.9%
- Gross Profit
- $471.88M+3.9%
- Op Income
- $231.09M
- Net Income
- $165.39M+266.9%
- EPS
- $1.94+263.0%
- OCF Growth
- +31.2%
- FCF Growth
- +36.9%
- 52W High
- $33.74
- 52W Low
- $17.23
- 50D MA
- $28.21
- 200D MA
- $24.56
- Beta
- 0.61
- RSI (14)
- 49
- Avg Volume
- 712.06K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Pediatrix reported a stronger-than-expected Q3, with adjusted EBITDA of $85 million and modest same-unit growth, while raising confidence in full-year 2026 EBITDA despite higher costs.· October 29, 2026
- Adjusted EBITDA was $85 million in Q3, and management narrowed full-year 2026 adjusted EBITDA guidance to $290 million-$300 million.
- Consolidated revenue increased by just under 2%, supported by recent acquisitions and same-unit growth of 60 basis points.
- Same-unit pricing rose 30 basis points, helped by payer mix, hospital admin fees, and higher acuity, even as the company began lapping prior collection-related tailwinds.
- The company bought back just over 3 million shares in the quarter; total repurchases since August 2025 reached 10 million shares, reducing shares outstanding to 78 million from 87 million at the end of Q2 2025.
- Management said ACA subsidy lapses had shown no clear negative effect so far, and out-of-network exposure remains less than 5% of the business.
Pediatrix said Q3 adjusted EBITDA was $85 million. Consolidated revenue increased by just under 2% year over year, and same-unit revenue grew 60 basis points, with same-unit patient service volumes up about 30 basis points and same-unit pricing also up 30 basis points. The company also said operating cash flow was $118 million versus $138 million in the prior-year quarter, cash was $312 million, net debt was just over $266 million, leverage was just under 1x, and accounts receivable DSO was 42.5 days, down just over half a day year over year. Management narrowed full-year 2026 adjusted EBITDA guidance to $290 million-$300 million. In the quarter, it repurchased just over 3 million shares; since August 2025, it has bought back 10 million shares at an average price of $23.
Mark Ordan framed the quarter as evidence that Pediatrix is executing well despite rising costs across the healthcare system. He emphasized the company’s focus on care quality, saying the annual medical-director meeting centered on quality rather than cost-cutting. He also said the company’s strong balance sheet gives it flexibility to invest internally, buy back stock, and consider larger adjacent acquisitions in women’s and children’s health, while he said the company does not expect the No Surprises Act IDR process to be a headwind because it follows the rules and is overwhelmingly in network.
Kasandra Rossi walked through revenue drivers, saying consolidated revenue rose just under 2% due to acquisitions and 60 basis points of same-unit growth. She said same-unit pricing was helped by payer mix, hospital admin fees, and acuity, while the company is now lapping the prior collection tailwind that had boosted pricing. On expenses, she noted SW&B rose year over year, G&A was higher due to incentive compensation, D&A was up about $700,000, and other nonoperating expense was $200,000 versus nonoperating income of $19.7 million last year because of a prior divestiture gain. She also said operating cash flow was $118 million, leverage was just under 1x, cash was $312 million, net debt was just over $266 million, and DSO was 42.5 days.
Analysts focused on how sustainable pricing is, especially the contribution from payer mix, hospital admin fees, acuity, and the RCM-related lap. Management said payer mix accounted for about 40% of the positive pricing impact, hospital admin fees about 25%, acuity about 15%, and the RCM lap hurt the quarter by a little over 100 basis points, but they view the drivers as generally sustainable. Questions also centered on the No Surprises Act IDR process, out-of-network exposure, and whether subsidy pressure on NICUs is increasing; Mark Ordan said out-of-network business has typically been less than 5%, the company is comfortable with the rules if they are fair, and NICU hospital-subsidy discussions are ongoing and based on demonstrating value, though he acknowledged a higher-pressure environment from the Big Beautiful Bill.
The company delivered a quarter that management said exceeded expectations, with EBITDA above the prior run rate and full-year guidance narrowed higher in confidence. Pricing held up despite lapping prior collection benefits, and management said payer mix, hospital fees, and acuity remain supportive. The balance sheet is strong, buybacks have been substantial, and management continues to see potential for adjacent acquisitions in women’s and children’s health.
Management acknowledged increasing costs in nearly all areas of care, including higher clinical salaries, G&A tied to incentive comp, and some pressure from the broader hospital environment. Pricing is now lapping a prior tailwind from improved collections, and management would not quantify how much of the NICU subsidy opportunity has already been captured, suggesting it could still be a negotiation-heavy process. They also said the coding changes for 2027 are not finalized yet, so the impact on OB hospitalist economics remains uncertain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.4%
- Shares Outstanding
- 78.12M
- Float Shares
- 76.88M
of shares held by institutions
306 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MD, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 13.51M | ▼ 200.31K |
| Vanguard Group Inc | 10.72M | ▼ 168.62K |
| Vanguard Portfolio Management LLC | 5.91M | ▼ 74.92K |
| Dimensional Fund Advisors LP | 4.41M | ▲ 185.59K |
| Vanguard Capital Management LLC | 3.61M | ▼ 9.65K |
| State Street Corp | 3.56M | ▲ 25.49K |
| Victory Capital Management Inc | 2.80M | ▼ 615.81K |
| Wasatch Advisors LP | 2.22M | ▼ 279.62K |
| Allspring Global Investments Holdings, LLC | 2.07M | ▲ 452.05K |
| Geode Capital Management, LLC | 2.06M | ▼ 164.25K |
| Lsv Asset Management | 1.73M | ▲ 536.84K |
| Fuller & Thaler Asset Management, Inc. | 1.70M | ▼ 23.39K |
Held by 390 ETFs
Biggest fund positions in MD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 10, 26 | Linynsky Laura A | sell | 6,000 |
| Aug 14, 26 | Young Sylvia Jean | sell | 18,500 |
| Aug 12, 26 | McEachin Thomas | other | 472 |
| Aug 12, 26 | Weis Shirley A | other | 472 |
| Aug 12, 26 | Starcher John M. Jr. | other | 472 |
| Aug 12, 26 | Linynsky Laura A | other | 472 |
| Aug 12, 26 | Newman Kurt Douglas | other | 472 |
| Aug 12, 26 | Rucker Michael A. | other | 472 |
| Aug 12, 26 | Young Sylvia Jean | other | 472 |
| Aug 12, 26 | SANSONE GUY P | other | 472 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MD coverage
Recent articles, reports, and earnings notes.
No research on MD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MD report →What Makes Pediatrix Medical Group (MD) a Strong Momentum Stock: Buy Now?
zacks.com · Nov 10
Pediatrix Medical Group (MD) Upgraded to Buy: Here's What You Should Know
zacks.com · Nov 6
Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock
zacks.com · Nov 6
What Pediatrix Medical Group (MD) Said on Its Q3 Earnings Call
marketbeat.com · Oct 30
Pediatrix Medical Group, Inc. (MD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Pediatrix Medical Group (MD) Beats Q3 Earnings and Revenue Estimates
zacks.com · Oct 29
Pediatrix Medical Group Reports Third Quarter Results
businesswire.com · Oct 29
Pediatrix Medical Group 2026 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 29, 2026
businesswire.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.